- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07792408
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Medical Information
- Telefoonnummer: 617-341-6777
- E-mail: medicalinfo@vrtx.com
Studie Locaties
-
-
-
Montreal, Canada
- Werving
- Altasciences - Beaumont Clinic Montreal
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m^2), inclusive
- A total body weight of greater than (>) 50 kg
Key Exclusion Criteria:
- History of febrile illness within 5 days before the first dose of study drug
- Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug
Other protocol defined Inclusion/Exclusion criteria will apply.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)
Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimenteel: Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)
Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimenteel: Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)
Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
|
Experimenteel: Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)
Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state. |
Tablets for Oral Administration. Combination Tablets for Oral Administration. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 9 and Day 23 up to Day 31
|
From Day 1 up to Day 9 and Day 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 5 and Day 19 up to Day 23
|
From Day 1 up to Day 5 and Day 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407
Tijdsspanne: From Day 1 up to Day 7 and Day 21 up to Day 27
|
From Day 1 up to Day 7 and Day 21 up to Day 27
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part B (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: From Day 1 Up to Day 39
|
From Day 1 Up to Day 39
|
|
Part C (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: From Day 1 up to Day 32
|
From Day 1 up to Day 32
|
|
Part D (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: From Day 1 up to Day 36
|
From Day 1 up to Day 36
|
|
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407
Tijdsspanne: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tijdsspanne: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tijdsspanne: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tijdsspanne: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tijdsspanne: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
|
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tijdsspanne: Days 11, 17 and 23 up to Day 31
|
Days 11, 17 and 23 up to Day 31
|
|
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tijdsspanne: Days 7, 13 and 19 up to Day 23
|
Days 7, 13 and 19 up to Day 23
|
|
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tijdsspanne: Days 9, 15 and 21 up to Day 27
|
Days 9, 15 and 21 up to Day 27
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ciliopathieën
- Urogenitale ziekten
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Genetische ziekten, aangeboren
- Aangeboren afwijkingen
- Afwijkingen, meerdere
- Nierziekten, Cystic
- Polycysteuze nierziekten
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Polycysteuze nier, autosomaal dominant
Andere studie-ID-nummers
- VX26-407-014
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .